menu
    • menu
    [{"orgOrder":0,"company":"Eli Lilly","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"FXR314","moa":"FXR","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7 (ITGA4\/B7)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Eli Lilly","amount2":3.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":3.2000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY3537021","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mark Feinglos","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Mark Feinglos","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Mark Feinglos"}]

    Find Gastroenterology Clinical Drug Pipeline Developments & Deals by Eli Lilly

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eli Lilly

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LY3537021,Dexamethasone,Cisplatin,Anthraxyline,Cyclophosphamide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With C...

                            Details : (LY3537021) is currently being evaluated in Phase II clinical studies for the treatment of Nausea.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 12, 2025

                            Lead Product(s) : LY3537021,Dexamethasone,Cisplatin,Anthraxyline,Cyclophosphamide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eli Lilly

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Recipient : Organovo Holdings

                            Deal Size : $60.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly Pays $10M Upfront for Organovo’s FXR Agonist Program

                            Details : Through the acquisition, Lilly will leverage FXR program of Organovo, which includes FXR314, it is being evaluated for the treatment of Inflammatory Bowel Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $10.0 million

                            February 25, 2025

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Recipient : Organovo Holdings

                            Deal Size : $60.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eli Lilly

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MORF-057

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Morphic Therapeutic

                            Deal Size : $3,200.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

                            Details : The acquisition expands Lilly's immunology pipeline with MORF-057, a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $3,200.0 million

                            July 08, 2024

                            Lead Product(s) : MORF-057

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Morphic Therapeutic

                            Deal Size : $3,200.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eli Lilly

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadalafil

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : Mark Feinglos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis

                            Details : Tadalafil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gastroparesis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 30, 2011

                            Lead Product(s) : Tadalafil

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : Mark Feinglos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.